Guardant Health (GH) Scheduled to Post Quarterly Earnings on Wednesday

Guardant Health (NASDAQ:GH) will release its earnings data after the market closes on Wednesday, August 7th. Analysts expect Guardant Health to post earnings of ($0.57) per share for the quarter. Guardant Health has set its FY 2024 guidance at EPS.Persons interested in listening to the company’s earnings conference call can do so using this link.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.94) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.94). Guardant Health had a negative net margin of 76.34% and a negative return on equity of 246.47%. The business had revenue of $168.49 million for the quarter, compared to analysts’ expectations of $150.51 million. On average, analysts expect Guardant Health to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Guardant Health Stock Up 2.9 %

Shares of NASDAQ GH opened at $36.29 on Wednesday. Guardant Health has a fifty-two week low of $15.81 and a fifty-two week high of $41.06. The firm’s 50-day simple moving average is $29.52 and its 200 day simple moving average is $23.55. The company has a debt-to-equity ratio of 16.70, a quick ratio of 5.66 and a current ratio of 5.95.

Analyst Ratings Changes

A number of brokerages recently weighed in on GH. The Goldman Sachs Group lifted their price objective on shares of Guardant Health from $28.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, July 17th. Canaccord Genuity Group lifted their target price on Guardant Health from $30.00 to $38.00 and gave the stock a “buy” rating in a report on Tuesday, June 4th. Jefferies Financial Group initiated coverage on Guardant Health in a report on Monday, June 3rd. They set a “buy” rating and a $32.00 target price on the stock. Stephens reaffirmed an “overweight” rating and set a $44.00 target price on shares of Guardant Health in a report on Friday, May 24th. Finally, Guggenheim raised Guardant Health from a “neutral” rating to a “buy” rating and set a $36.00 target price on the stock in a report on Friday, June 28th. One research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $38.29.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.